RBC Capital provided its review on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), noting it sees a favorable set-up into SEQUOIA top-line data on Monday next week.

According to the analysts, some noise is possible given small n/liver biopsy have limitations, but they are fundamental believers in the therapeutic hypothesis given the consistency across endpoints seen to date and endorsed by the FDA via BTD. The pathophysiology of the disease is well understood, and the analysts like that prior data showed a signal that was consistent across all endpoints. The analysts maintained their Outperform rating and $83 price target on the company’s shares.